Short report of a phase ii trial of nintedanib in recurrent malignant pleural mesothelioma (MPM) Journal Article

   


Authors: Wozniak, A. J.; Schneider, B.; Kalemkerian, G. P.; Daly, B.; Chen, W.; Ventimiglia, J.; Nagasaka, M.; Zauderer, M. G.
Article Title: Short report of a phase ii trial of nintedanib in recurrent malignant pleural mesothelioma (MPM)
Abstract: • Novel therapies are needed for the treatment of malignant pleural mesothelioma (MPM). • Agents targeting angiogenesis such as bevacizumab have a role in the treatment of MPM. • Nintedanib had modest activity involving prolonged stable disease in a small group of patients. • Immunotherapy is now important in the treatment of MPM but angiogenesis inhibitors in combination with immunotherapy and/or chemotherapy may still have a role. • It is very important to discover biomarkers that can help with patient selection to individualize treatment. • Participation in clinical trials evaluating novel agents remains very important in advancing treatment strategies. © 2023
Keywords: adult; cancer survival; clinical article; treatment response; aged; survival rate; overall survival; clinical trial; fatigue; cancer recurrence; case report; bevacizumab; ascites; diarrhea; drug withdrawal; follow up; anorexia; edema; progression free survival; drug eruption; lung toxicity; pain; phase 2 clinical trial; neoplasm recurrence, local; blood toxicity; nausea; vomiting; lung neoplasms; pathology; angiogenesis; dyspnea; lung embolism; lung tumor; survival time; tumor recurrence; thrombosis; malignant mesothelioma; pleura mesothelioma; mesothelioma; pleura tumor; platinum derivative; heart arrhythmia; tyrosine kinase inhibitor; sarcomatoid; pemetrexed; metabolic disorder; pleural neoplasms; vegf; epithelioid; hypertransaminasemia; faintness; humans; human; male; female; article; nintedanib; mesothelioma, malignant
Journal Title: Clinical Lung Cancer
Volume: 24
Issue: 6
ISSN: 1525-7304
Publisher: Elsevier Inc.  
Date Published: 2023-09-01
Start Page: 563
End Page: 567
Language: English
DOI: 10.1016/j.cllc.2023.04.004
PUBMED: 37301693
PROVIDER: scopus
PMCID: PMC11233026
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85163761989&doi=10.1016%2fj.cllc.2023.04.004&partnerID=40&md5=e55061a5c2dc964776e346eab166d763
Notes: Article -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Marjorie G Zauderer
    188 Zauderer
  2. Robert M Daly
    78 Daly
Related MSK Work